<?xml version="1.0" encoding="UTF-8"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-10-18T23:51:05Z</responseDate><request verb="GetRecord" identifier="oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/13559" metadataPrefix="oai_dc">https://ebyu-rdlopen.rawdatalibrary.net/oai/request</request><GetRecord><record><header><identifier>oai:ebyu-rdlopen.rawdatalibrary.net:ebyu/13559</identifier><datestamp>2026-10-18T21:14:20Z</datestamp><setSpec>openaire</setSpec><setSpec>driver</setSpec><setSpec>com_ebyu_10000</setSpec><setSpec>col_ebyu_10001</setSpec></header><metadata><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd"><dc:title>Could interleukin-33 and its suppressor of tumorigenicity 2 (ST2) receptor have a role in cervical human papillomavirus (HPV) infections?</dc:title><dc:creator>Kulhan, Nur Gozde</dc:creator><dc:creator>Kulhan, Mehmet</dc:creator><dc:creator>Aydin, Merve</dc:creator><dc:creator>Nayki, Umit</dc:creator><dc:creator>Nayki, Cenk</dc:creator><dc:creator>Ulug, Pasa</dc:creator><dc:creator>Ata, Nahit</dc:creator><dc:creator>Mertoglu, Cuma</dc:creator><dc:creator>Cikman, Aytekin</dc:creator><dc:creator>Sayar, İlyas</dc:creator><dc:creator>Turkler, Can</dc:creator><dc:subject>cervical cancer</dc:subject><dc:subject>Human papillomavirus</dc:subject><dc:subject>interleukin-33</dc:subject><dc:subject>receptor</dc:subject><dc:subject>suppressor of tumorigenicity 2 (ST2)</dc:subject><dc:subject>Adult</dc:subject><dc:subject>Aged</dc:subject><dc:subject>Biopsy</dc:subject><dc:subject>Cervical Intraepithelial Neoplasia</dc:subject><dc:subject>Cervix Uteri</dc:subject><dc:subject>Cohort Studies</dc:subject><dc:subject>Enzyme-Linked Immunosorbent Assay</dc:subject><dc:subject>Female</dc:subject><dc:subject>Humans</dc:subject><dc:subject>Interleukin-1 Receptor-Like 1 Protein</dc:subject><dc:subject>Middle Aged</dc:subject><dc:subject>Papillomaviridae</dc:subject><dc:subject>Papillomavirus Infections</dc:subject><dc:subject>Reproductive Tract Infections</dc:subject><dc:subject>Uterine Cervical Neoplasms</dc:subject><dc:subject>Vaginal Smears</dc:subject><dc:subject>Young Adult</dc:subject><dc:subject>interleukin 33</dc:subject><dc:subject>suppressor of tumorigenicity 2 receptor</dc:subject><dc:subject>unclassified drug</dc:subject><dc:subject>IL1RL1 protein, human</dc:subject><dc:subject>IL33 protein, human</dc:subject><dc:subject>interleukin 1 receptor like 1 protein</dc:subject><dc:subject>Article</dc:subject><dc:subject>cancer screening</dc:subject><dc:description>Why most women can clear human papillomavirus (HPV) infections while others can develop permanent infections. The stimulation of immunotolerance of the immune system of the host by the persistent HPV infection may be the answer to this question. Interleukin-33 (IL-33) may play a role in the pathogenesis of HPV infection, this hypothesis was thought to be due to the rapid release of IL-33 from damaged cells following tissue damage, necrosis, and activation of the inflammasome. Thus, in this study, the role of IL-33/suppressor of tumorigenicity 2 (ST2) was emphasized in HPV positive and HPV negative cervical tissues. A total of 80 were assessed. The reduced levels of IL-33 and ST2 are associated with cervical HPV infections. There was a statistically significant 42% positive correlation between IL-33 and ST2 in the HPV-positive group. Surprisingly, our data showed no significant difference between the expression levels of IL-33 or ST2 and working status, type of delivery, pre- and post-operative pathology, cigarette, educational status, locality, birth control method, gynecological, and colposcopic findings. We found that as a result of our study; low IL-33 and ST2 levels were associated with HPV infections. © 2019, © 2019 Informa UK Limited, trading as Taylor &amp; Francis Group.</dc:description><dc:publisher>Taylor and Francis Ltd</dc:publisher><dc:date>2019</dc:date><dc:type>Article</dc:type><dc:identifier>https://rdlopen.rawdatalibrary.net/r/ebyu/13559</dc:identifier><dc:identifier>https://doi.org/10.1080/09513590.2019.1590699</dc:identifier><dc:identifier>0951-3590</dc:identifier><dc:language>en</dc:language><dc:relation>Gynecological Endocrinology</dc:relation><dc:rights>info:eu-repo/semantics/openAccess</dc:rights><dc:type>info:eu-repo/semantics/article</dc:type><dc:identifier>https://ebyu-rdlopen.rawdatalibrary.net/tr/items/ebyu/13559</dc:identifier></oai_dc:dc></metadata></record></GetRecord></OAI-PMH>